MedTrace Logo

Squamous Cell Carcinoma of the Head and Neck

Disease

Related News

CEL-SCI to Begin U.S. Registration Study for Multikine in Summer 2026, Pursues Saudi Partnership

CEL-SCI plans to start patient enrollment in summer 2026 for a 212-patient U.S. registration study of its cancer immunotherapy Multikine, with the goal of seeking early accelerated approval. The company is also advancing a strategic partnership with Saudi Amarox to commercialize Multikine in Saudi Arabia, where it has submitted a Breakthrough Medicine Designation application. These initiatives build on Phase 3 data showing Multikine improved 5-year survival in head and neck cancer patients from 45% to 73%.

Related Clinical Trials

NCT ID Title Status Phase
NCT06223568

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

 ACTIVE_NOT_RECRUITING PHASE2
NCT05208762

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

 RECRUITING PHASE1
NCT04881045

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

 COMPLETED PHASE1
NCT04609566

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

 COMPLETED PHASE2
NCT04290546

CIML NK Cell in Head & Neck Cancer

 COMPLETED PHASE1
NCT03712566

Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy

 ACTIVE_NOT_RECRUITING
NCT03690986

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

 ACTIVE_NOT_RECRUITING PHASE1
NCT03139058

Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck

 TERMINATED NA
NCT02296684

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

 COMPLETED PHASE2